Literature DB >> 16333862

Bone marrow transplantation from matched related donors for patients with Fanconi anemia using low-dose busulfan and cyclophosphamide as conditioning.

L Torjemane1, S Ladeb, T Ben Othman, A Abdelkefi, A Lakhal, A Ben Abdeladhim.   

Abstract

Seventeen patients with Fanconi anemia (FA) underwent allogeneic bone marrow transplantation (BMT) from matched related donors (MRD) between January 1999 and June 2003. Median age at BMT was 11 years. Conditioning regimen consisted of low-dose cyclophosphamide (CY; 40 mg/kg) and busulfan (BU; 6 mg/kg) with the addition of lymphoglobulin (20 mg/kg) in two patients. Graft-versus-host disease (GVHD) prophylaxis included cyclosporine A (CsA) and methotrexate (MTX; 5 mg/m(2) at day 1, 3, 6). All patients engrafted (for an absolute neutrophil count >0.5 x 10(9)/L) after a median time of 12 days (range 10-16 days). Fourteen patients (82%) had sustained grafts, whereas three others (18%) rejected grafts between day +39 and +80 after transplantation. Two of them are still alive after successful second PBSC transplantation and one died. Acute and chronic GVHD occurred in 23% and 13% of patients, respectively. With a median follow-up of 16 months (range 3-53 months), survival rate was 72% and Karnofsky score was at least 90%. The low-dose BU/CY regimen, in FA patients allografted from an HLA-matched related donor, allowed engraftment with relative low toxicity. Early graft failure (GF) remains a problem and may require modification of this regimen.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16333862     DOI: 10.1002/pbc.20286

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  7 in total

1.  Cyclophosphamide promotes engraftment of gene-modified cells in a mouse model of Fanconi anemia without causing cytogenetic abnormalities.

Authors:  Jennifer E Adair; Xin Zhao; Sylvia Chien; Min Fang; Martin E Wohlfahrt; Grant D Trobridge; Jason A Taylor; Brian C Beard; Hans-Peter Kiem; Pamela S Becker
Journal:  J Mol Med (Berl)       Date:  2012-06-03       Impact factor: 4.599

2.  Busulfan Pharmacokinetics and Precision Dosing: Are Patients with Fanconi Anemia Different?

Authors:  Parinda A Mehta; Chie Emoto; Tsuyoshi Fukuda; Brian Seyboth; Ashley Teusink-Cross; Stella M Davies; Jamie Wilhelm; Kirsten Fuller; Alexander A Vinks; Farid Boulad
Journal:  Biol Blood Marrow Transplant       Date:  2019-07-18       Impact factor: 5.742

3.  Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study.

Authors:  Parinda A Mehta; Stella M Davies; Thomas Leemhuis; Kasiani Myers; Nancy A Kernan; Susan E Prockop; Andromachi Scaradavou; Richard J O'Reilly; David A Williams; Leslie Lehmann; Eva Guinan; David Margolis; K Scott Baker; Adam Lane; Farid Boulad
Journal:  Blood       Date:  2017-02-08       Impact factor: 22.113

4.  Fludarabine- and low-dose cyclophosphamide-based conditioning regimens provided favorable survival and engraftment for unmanipulated hematopoietic cell transplantation from unrelated donors and matched siblings in patients with Fanconi anemia: results from the CBMTR.

Authors:  Lanping Xu; Yue Lu; Jing Chen; Shuwen Sun; Shaoyan Hu; Shunqing Wang; Xuedong Wu; Yuan Sun; Dingming Wan; Yajing Xu; Hui Jiang; Chunfu Li; Mei Lan; Erlie Jiang; Fei Li; Sixi Liu; Yongmin Tang; Fan Lin; Peihua Lu; Chengjuan Luo; Xiaojun Huang
Journal:  Bone Marrow Transplant       Date:  2022-10-18       Impact factor: 5.174

Review 5.  Fanconi anaemia and cancer: an intricate relationship.

Authors:  Grzegorz Nalepa; D Wade Clapp
Journal:  Nat Rev Cancer       Date:  2018-01-29       Impact factor: 60.716

6.  Successful bone marrow transplantation in a patient with DNA ligase IV deficiency and bone marrow failure.

Authors:  Bernd Gruhn; Joerg Seidel; Felix Zintl; Raymonda Varon; Holger Tönnies; Heidemarie Neitzel; Astrid Bechtold; Holger Hoehn; Detlev Schindler
Journal:  Orphanet J Rare Dis       Date:  2007-01-15       Impact factor: 4.123

7.  Use of the cell division assay to diagnose Fanconi anemia patients' hypersensitivity to mitomycin C.

Authors:  Ola Hammarsten; Aida Muslimovic; Sofia Thunström; Torben Ek; Pegah Johansson
Journal:  Cytometry B Clin Cytom       Date:  2020-08-28       Impact factor: 3.058

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.